Comments on: FDA Issues Approvable for Acomplia for Weight Loss; Not Approvable for Smoking Cessation http://pharmaweblog.com/blog/2006/02/18/fda-issues-approvable-for-acomplia-for-weight-loss-not-approvable-for-smoking-cessation/ Pharmaceutical and biotech science and business Wed, 20 Aug 2008 10:51:30 +0000 http://wordpress.org/?v=2.0.2 by: Pharma’s Cutting Edge » FDA puts to rest notion of metabolic syndrome indication for Acomplia, other weight loss drugs http://pharmaweblog.com/blog/2006/02/18/fda-issues-approvable-for-acomplia-for-weight-loss-not-approvable-for-smoking-cessation/#comment-45 Thu, 15 Feb 2007 16:33:58 +0000 http://pharmaweblog.com/blog/2006/02/18/fda-issues-approvable-for-acomplia-for-weight-loss-not-approvable-for-smoking-cessation/#comment-45 [...] Following FDA’s non-approvable decision for rimonabant (Acomplia) last year, I referred to Sanofi-Aventis’ pursuit of an indication for the metabolic syndrome as “kakameyme”.  Seems like FDA’s Metabolic and Endocrine Division (DMEDP) agrees with me. [...] […] Following FDA’s non-approvable decision for rimonabant (Acomplia) last year, I referred to Sanofi-Aventis’ pursuit of an indication for the metabolic syndrome as “kakameyme”.  Seems like FDA’s Metabolic and Endocrine Division (DMEDP) agrees with me. […]

]]>